F. Hoffmann-La Roche Ltd, Pharmaceutical Research Basel, Discovery Chemistry, CH-4070 Basel, Switzerland.
Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4. doi: 10.1016/j.bmcl.2009.08.053. Epub 2009 Aug 15.
Lead optimisation of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine class led to the identification of two clinical leads [RO4882224 (11) and RO4938581 (44)] functioning as novel potent and selective GABAA alpha5 inverse agonists. The unique pharmacological profiles and optimal pharmacokinetic profiles resulted in in vivo activity in selected cognition models.
先导化合物的优化使得咪唑并[1,5-a][1,2,4]三氮唑并[1,5-d][1,4]苯并二氮杂䓬类化合物中鉴定出两个临床前候选化合物[RO4882224(11)和 RO4938581(44)],它们作为新型有效的、选择性 GABAAα5 反向激动剂。独特的药理学特性和最佳的药代动力学特性使其在选定的认知模型中具有体内活性。